Slide 1: Welcome Investors
WelcomeInvestors Welcome Investors August March 2025 2022
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements in this presentation may be considered “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally relate to future events or th
Slide 3: Who We Are
Who We Are Key Stats: Headquarters: Ticker: Established: Newburyport, MA UFPT 1963 UFP Technologies is a contract development and manufacturing organization (CDMO) that specializes in single use polymer Annual Revenue: Market Cap: 26 of top 30 based, medical devices ~$600 million 1 ~$1.95 Billion2 M
Slide 4: Shaping Innovation
Design & engineering capabilities Materials expertise Shaping Innovation Precision manufacturing Strategic locations 4
Slide 5: Our Process
Customer Design & Development POSSESS Tooling Our Process Custom Quality Pilot Commercial Equipment Systems Manufacturing Production LE a)
Slide 6: Product Development Business
Product Development Business High Margin Added Expertise 1 2 We bring deep experience in flexible material-based device manufacturing, from components and packaging, to BENEFITS final device assembly 3 4 Long Term Stronger Customer Relationships Manufacturing 6
Slide 7: MedTech Portfolio
MedTech Portfolio Robotic Drapes Revascularization Needleless Injection Device Port Cleaner MedSurg Bed Negative Pressure Patient Safety Wound Therapy 7
Slide 8: MedTech
MedTech MedTech Revenue by Segment3 $518 billion, 6.3% CAGR1 Global Medical Device Market Customers include 26 of the top 30 largest medical device manufacturers in the world2 Packaging 16% Global Medical Device CDMO Market4: $101B | 11% CAGR Devices UFP is uniquely focused on three RAS 55% medical
Slide 9: Medical Segment Overview
Medical Segment Overview $518 Billion Global Device Market, 6.3% CAGR1 Therapeutic Area % of Medical Market Sales2 Growth Robotic Surgery 29% Mid Teens Surfaces & Support 23% LDD Interventional & Surgical 20% LSD Infection Prevention 9% MSD Orthopedics 6% MSD Therapeutics 3% MSD Wound Care 4% MSD Di
Slide 10: Surrounding a High-Growth End Market: Robotic Surgery
Surrounding a High-Growth End Market: Robotic Surgery ROBOTIC SURGERY BY THE NUMBERS Acquisition strategy centered upon UFPT is the leading provider of several adding core capabilities to our • Market Size: ~$11B (2024) → ~$23.7B (2029)1 materials / capabilities that are critical for robotic surgery
Slide 11: Growth Strategy
Growth Strategy TWO-PRONGED Internal Growth: Strategic Acquisitions Market To Our Sweet Spot 1 1
Slide 12: Organic Growth Opportunity
Market to our sweet spot and differentiated capabilities » Leverage technology differentiation » Engineering resources » Exclusive access to specialty materials » Scale (footprint, clean room manufacturing) Organic Expand business with existing customers Growth » Offer complementary products and ser
Slide 13: Acquisition Growth Opportunity
Continue to Focus on Higher-Growth, Higher-Margin MedTech Opportunities that Create Value » Become more valuable to our customers » Strategic focus – new capability, geography, growing market segment, materials Acquisition » Add scale Growth » Look for synergistic opportunities » Cultural fit Opport
Slide 14: Proven Acquisition Integration
ProvenCentric Customer Acquisition Integration MedTech M&A ModelDifferentiated Tech – Growing Segments, MedTech Sales Over Time $540 million 700,000,000 MedTech $451 million 600,000,000 MedTech 500,000,000 400,000,000 $132 million 300,000,000 MedTech 200,000,000 100,000,000 0 2021 2022 2023 2024 202
Slide 15: Why Invest?
Why Invest? Significant Barriers Strong Experienced Proven Attractive market to entry customer management growth financial growth relationships team strategy metrics opportunities 1 5
Slide 16: Significant Market Growth Opportunities
Focused on fast growing segments Significant Market Growth Market Focused On » Better Patient Outcomes Opportunities » Infection Prevention » Reducing Healthcare Costs Global Footprint » Bringing New Opportunities 16
Slide 17: Competitive Advantage
Competitive Advantage Greater Access to Engineering Resources Custom Equipment Materials » Veteran engineering team for » Exclusive access to several specialty » In-house custom equipment product design and development; medical grade materials manufacturing capabilities more than 100 members of the
Slide 18: Proven Growth Strategy
Proven Growth Creating Shareholder Value Strategy 18
Slide 19: Financial Targets
Financial Targets 19
Slide 20: Financial Targets
Financial Targets 3 to 5 Year Financial Targets 12-18% 28-31% 17-20% Revenue Growth Gross Margin Adjusted Operating Margin 20
Slide 21: Revenue
Revenue $700 $600 $500 $400 12% to 18% $300 Targeted Revenue Growth $200 Internal Growth + Acquisitions $100 $0 2020 2021 2022 2023 2024 June 2025 TTM TTM = 12-month period ended June 30, 2025 21
Slide 22: Gross Profit Margin
Gross Profit 32.0% Margin 30.0% Target: 28-31% 29.1% 28.6% 28.1% 28.0% 26.0% 25.5% 24.9% 24.8% Gross Margin 24.0% Target – 28% to 31% 22.0% Operating Leverage from Mix Shift + Acquisition 20.0% synergies + Efficiencies 18.0% 2020 2021 2022 2023 2024 Q2 YTD 22
Slide 23: Adjusted Operating Margin
Adjusted* Operating 20.0% Target: 17-20% 18.3% Margin 17.7% 16.4% 15.0% 13.8% 11.1% 10.3% 10.0% Adjusted Operating Margin Target - 17% to 20% 5.0% Operating leverage from mix shift + acquisition synergies + efficiencies 0.0% 2020 2021 2022 2023 2024 Q2 YTD *See non-GAAP reconciliation on slide 32 23
Slide 24: UFP Historical Stock Performance
11000% 10000% 9000% 8000% 7000% 6496% 6000% 5000% UFP Historical 4000% 3000% Stock 2000% Performance 1000% 414% 20 Years 0% 236% UFP Technologies (UFPT) Price % Change Russell 2000 (RUT) Price % Change S&P 500 (SPX) Price % Change *Measured as the percent increase from August 5, 2005 through August
Slide 25: Contact
Mitch Rock President Newburyport, Massachusetts Ron Lataille CFO, Sr. VP & Treasurer Newburyport, Massachusetts UFP Technologies Newburyport, MA 01950 www.ufpt.com 100 Hale St. 978-352-2200 investorinfo@ufpt.com
Slide 26: Appendix: Reconciliation of Non-GAAP Results
Appendix Reconciliation of Non-GAAP Results (in Millions) 2020 2021 2022 2023 2024 Q2 2025 Revenue, As Reported $ 179.4 $ 206.3 $ 353.8 $ 400.1 $ 504.4 $ 299.3 Operating Income, as Reported 16.7 21.2 55.4 57.7 80.9 47.5 Add: Purchase Accounting Expenses - - - - 1.1 - Add: Acquisition Related Costs -